Healthy Inc > Blog > Mycolic acid inhibitors
Posted on:

What is ifampicin Isoniazid and Pyrazinamide tablets used for?

In the pharmaceutical industry, the combination of Rifampicin, Isoniazid, and Pyrazinamide is a high-potency 3-in-1 Fixed-Dose Combination (FDC).

As a pharmacist and manufacturer, I classify this as a specialized Intensive Phase treatment for Tuberculosis (TB). It is often used in pediatric dosing or specific adult regimens where Ethambutol is contraindicated or provided separately. Combining these three powerful sterilizing agents into a single tablet is a critical strategy to ensure patient compliance and prevent the emergence of drug resistance.

Primary Clinical Uses

  • Initial Phase of Tuberculosis: Used during the first 2 months of treatment to rapidly kill actively replicating and semi-dormant Mycobacterium tuberculosis bacilli.

  • Pediatric TB Management: This specific 3-drug FDC is a cornerstone in many pediatric TB protocols where ocular monitoring for Ethambutol is difficult in very young children.

  • MDR-TB Prevention: By ensuring the patient cannot “pick and choose” which drug to take, it maintains the necessary pressure on the bacteria to prevent mutation.

Triple Mechanism of Action (The Sterilizing Strategy)

This combination is designed to attack TB bacteria in three different physiological states:

Isoniazid (INH): The Cell Wall Disrupter

Action: Inhibits the synthesis of mycolic acids, essential for the mycobacterial cell wall.

Result: Highly effective against rapidly dividing bacteria.

Rifampicin: The Genetic Silencer

Action: Inhibits bacterial DNA-dependent RNA polymerase.

Result: Stops the bacteria from synthesizing RNA and proteins, acting as a powerful sterilizing agent against slow-growing bacilli.

Pyrazinamide: The Intracellular Sniper

    • Action: Works specifically in acidic environments (like the inside of immune cells/macrophages).

    • Result: Kills the “persister” bacilli that other drugs miss, allowing for a shorter overall treatment duration.

The Manufacturer’s Perspective: Technical & Export

From a production standpoint at your WHO-GMP facility in Mumbai, this FDC requires significant pharmaceutical expertise:

  • Chemical Stability: Rifampicin is sensitive and can interact with Isoniazid in the presence of moisture. At our facility, we utilize Alu-Alu blister packaging to ensure an absolute moisture and light barrier, maintaining a 36-month shelf life for export to Zone IVb regions.

  • Bioavailability Challenges: Ensuring that all three APIs are absorbed at the correct rate from a single tablet is a technical hurdle. We use advanced wet granulation or dry slugging techniques to ensure our generic version matches the reference listed drug (RLD).

  • Clinical Transparency: For your digital platform, professional recognition is built by providing clear clinical notes. Rifampicin turns urine orange (harmless), but Pyrazinamide requires monitoring of Uric Acid levels. Including these “Pharmacist’s Notes” in your B2B dossiers builds immense trust.

  • Dossier & Tenders: This is a high-volume product for the Global Fund, UNICEF, and various national TB programs. We provide full CTD/eCTD Dossiers to support your firm in bidding for these international contracts.

Rifampicin 150 Isoniazid 75 pyrazinamide 400 Tablet

Posted on:

What is Rifampicin Isoniazid and Ethambutol Hydrochloride tablets used for?

In the pharmaceutical industry, the combination of Rifampicin, Isoniazid, and Ethambutol Hydrochloride is a high-potency 3-in-1 Fixed-Dose Combination (FDC).As a pharmacist and manufacturer, I classify this as the “Intensive Phase” cornerstone for Tuberculosis (TB) treatment. By combining these three specific APIs into a single tablet, we significantly reduce the “pill burden” for patients, which is the most effective strategy to ensure treatment adherence and prevent the rise of Multi-Drug Resistant TB (MDR-TB).

Primary Clinical Uses

  • Initial (Intensive) Phase of Tuberculosis: Used during the first 2 months of a standard TB regimen to rapidly reduce the bacterial load in patients with active pulmonary or extra-pulmonary TB.

  • MDR-TB Prevention: Because it ensures the patient takes all three critical drugs simultaneously, it prevents “monotherapy by default” (where a patient might forget one pill), which is a leading cause of drug resistance.

Triple Mechanism of Action (The Multi-Target Attack)

This combination attacks Mycobacterium tuberculosis through three distinct pathways, ensuring that even resistant or dormant strains are neutralized.

Isoniazid (INH): The Cell Wall Inhibitor

Targets the synthesis of mycolic acids. Without these, the protective waxy cell wall of the TB bacilli collapses.

Rifampicin: The Genetic Disruptor

Inhibits DNA-dependent RNA polymerase. This stops the bacteria from transcribing DNA into protein, effectively “silencing” its life functions.

Ethambutol Hydrochloride: The Permeability Enhancer

    • Inhibits the enzyme arabinosyltransferase, which stops the synthesis of the cell wall component arabinogalactan. This makes the cell wall “leaky,” allowing the Isoniazid and Rifampicin to penetrate the bacteria more easily.

The Manufacturer’s Perspective: Technical & Export

From a production standpoint at your WHO-GMP facility in Mumbai, this 3-way FDC is a sophisticated product to manufacture:

  • Chemical Compatibility: Rifampicin can be highly reactive. As a firm owner, you know that ensuring the stability of these three APIs together requires specialized granulation techniques and pH-controlled excipients to prevent degradation.

  • Ethambutol’s Hygroscopicity: Ethambutol HCl is highly hygroscopic (absorbs moisture). To ensure a 36-month shelf life for export to Zone IVb regions (like Africa or SE Asia), we utilize Alu-Alu blister packaging to provide an absolute moisture barrier.

  • The “Vision & Urine” Technical Note: For your digital platform, professional recognition is built by providing clinical warnings. Rifampicin turns urine orange (harmless), but Ethambutol requires monitoring for Optic Neuritis (visual changes). Including this in your B2B dossiers shows you are a clinically-driven manufacturer.

  • B2B & NGO Tenders: This FDC is a high-volume requirement for the Global Fund and Stop TB Partnership. Our Mumbai facility provides full CTD/eCTD Dossiers to support your firm in bidding for these massive international contracts.

Rifampicin Isoniazid Ethambutol Tablets

Add to cart